Compare
Imcivree vs. Zepbound

Imcivree (setmelanotide) is an injectable medication for adults and children with certain rare conditions. It's FDA approved for acquired hypothalamic obesity (HO). It's also approved to help with obesity caused by some genetic conditions. These are Bardet-Biedl syndrome (BBS) and POMC, PCSK1, or LEPR deficiency. The medication works as a melanocortin agonist. It lessens appetite and makes the body use more energy, leading to weight loss. It's injected under the skin once a day. Side effects include darkening of skin color and nausea. More serious risks include depression and suicidal thoughts.

• Weight loss and long-term weight management in people ages 4 years and older with obesity due to damage to the hypothalamus (acquired hypothalamic obesity, HO)

• Weight loss and long-term weight management in people ages 2 years and older with obesity due to certain genetic conditions:

  • POMC deficiency
  • PCSK1 deficiency
  • Leptin receptor (LEPR) deficiency
  • Bardet-Biedl syndrome (BBS)

• Darkening or discoloration of the skin (58%)
• Nausea (55%)
• Vomiting (38%)
• Headache (37%)
• Moles (new, larger, or darker ones; 15%)
• Constipation (12%)
• Dizziness (12%)
• Mouth or throat pain (11%)

• Problems with sexual function
• Depression and suicidal thoughts
• Allergic reactions
• Darkening of your skin or moles and appearance of new moles
• Adrenal insufficiency in people with acquired HO
• Abnormal sodium levels in people with acquired HO and central diabetes insipidus

Zepbound (tirzepatide) is an injectable medication that's used along with diet and exercise. It helps with weight loss in adults who meet criteria for weight management therapy. It's also approved to treat moderate-to-severe sleep apnea. This medication belongs to the drug class called GIP and GLP-1 agonists. The dosage is 1 injection under the skin once a week. Common side effects include nausea, diarrhea, and injection site reactions. Zepbound (tirzepatide) is only available as a brand-name medication.

In addition to a balanced diet and exercise plan:

• Weight loss and long-term weight management in adults considered obese or overweight with at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes)
• Moderate-to-severe obstructive sleep apnea (OSA) in adults considered obese

• Nausea (25-29%)
• Diarrhea (19-23%)
• Constipation (11-17%)
• Vomiting (8-13%)
• Stomach pain (9-10%)
• Indigestion (9-10%)

• Risk of thyroid cancer
• Stomach problems
• Kidney damage
• Gallbladder problems
• Inflammation of the pancreas (pancreatitis)
• Allergic reactions
• Low blood sugar (hypoglycemia)
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Lung problems during general anesthesia or deep sedation
• Don't share Zepound KwikPens with anyone